Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ConforMIS

This article was originally published in The Gray Sheet

Executive Summary

Firm's second generation iUni unicompartmental knee resurfacing system is the only such device on the market with patient-specific jig instrumentation, which reduces the number of surgical steps during knee replacement, according to ConforMIS VP, Engineering John Slamin. The second-generation system, which launched last month after receiving 510(k) clearance, also features an improved design that reduces wear and iView patient-specific planning images that improve visualization for surgeons. The first-generation iUni launched in early 2008. ConforMIS also is preparing to file a 510(k) for its iTotal tri-compartmental knee resurfacing system (1"The Gray Sheet" July 13, 2009)

You may also be interested in...



ConforMIS Plans 2010 Launch Of Personalized Total Knee Device

Personalized orthopedic implant maker ConforMIS will use the proceeds from a recently completed $50 million "Series D" financing round to expand its commercial infrastructure in preparation for a 2010 launch of its iTotal tri-compartmental knee resurfacing system, according to the company

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

Topics

UsernamePublicRestriction

Register

MT028265

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel